These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38771399)

  • 1. Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer.
    White O; Dent S; Westbrook K; Lee HJ; Yang C; Moore HN
    Breast Cancer Res Treat; 2024 Aug; 207(1):179-185. PubMed ID: 38771399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab for Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
    N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
    Sikov WM; Berry DA; Perou CM; Singh B; Cirrincione CT; Tolaney SM; Kuzma CS; Pluard TJ; Somlo G; Port ER; Golshan M; Bellon JR; Collyar D; Hahn OM; Carey LA; Hudis CA; Winer EP
    J Clin Oncol; 2015 Jan; 33(1):13-21. PubMed ID: 25092775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
    Pusztai L; Denkert C; O'Shaughnessy J; Cortes J; Dent R; McArthur H; Kümmel S; Bergh J; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Zhu Y; Pan W; Tryfonidis K; Schmid P
    Ann Oncol; 2024 May; 35(5):429-436. PubMed ID: 38369015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.
    Dent R; Cortés J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Haiderali A; Jia L; Nguyen AM; Pan W; O'Shaughnessy J; Schmid P
    J Natl Cancer Inst; 2024 Oct; 116(10):1654-1663. PubMed ID: 38913881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
    N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
    Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
    Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
    Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
    Fasching PA; Hein A; Kolberg HC; Häberle L; Uhrig S; Rübner M; Belleville E; Hack CC; Fehm TN; Janni W; Hartmann A; Erber R; Theuser AK; Brucker SY; Hartkopf AD; Untch M
    Eur J Cancer; 2023 May; 184():1-9. PubMed ID: 36871424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
    Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
    Morris PG; Dickler M; McArthur HL; Traina T; Sugarman S; Lin N; Moy B; Come S; Godfrey L; Nulsen B; Chen C; Steingart R; Rugo H; Norton L; Winer E; Hudis CA; Dang CT
    J Clin Oncol; 2009 Dec; 27(36):6117-23. PubMed ID: 19901120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.
    Castrellon AB; Velez M; Nguyen SM; Blaya M; Barnick S; Dumais K; LeCroy N; Raez LE
    Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):30-33. PubMed ID: 29100977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer.
    Mai N; Myers S; Shen S; Downs-Canner S; Robson M; Norton L; Chen Y; Traina T; Abuhadra N
    NPJ Breast Cancer; 2024 Jun; 10(1):39. PubMed ID: 38834621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
    Yardley DA; Arrowsmith ER; Daniel BR; Eakle J; Brufsky A; Drosick DR; Kudrik F; Bosserman LD; Keaton MR; Goble SA; Bubis JA; Priego VM; Pendergrass K; Manalo Y; Bury M; Gravenor DS; Rodriguez GI; Inhorn RC; Young RR; Harwin WN; Silver C; Hainsworth JD; Burris HA
    Breast Cancer Res Treat; 2017 Aug; 164(3):649-658. PubMed ID: 28508185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
    Georgy JT; Singh A; John AO; Joel A; Andrews AG; Thumaty DB; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Paul MJ; Balakrishnan R; Backianathan S; Chacko RT
    Klin Onkol; 2021; 34(1):49-55. PubMed ID: 33657819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
    Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
    Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.